# Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments

## TL;DR

This paper discusses a case where a patient with relapsed lymphoma showed prolonged responses after CAR-T cell therapy using targeted treatments.

## Contribution

The paper presents a novel approach to sustaining CAR-T cells after relapse in DLBCL.

## Key findings

- The patient relapsed after third-line tisagenlecleucel treatment.
- Treatment strategies aimed to sustain circulating CAR-T cells were effective.
- CAR-T cell kinetics were monitored during these treatments.

## Abstract

The introduction of chimeric antigen receptor T-cell (CAR-T cell) therapy has changed the treatment landscape of diffuse large B-cell lymphoma (DLBCL). However, the optimal treatment strategy after relapse after this therapy still needs to be elucidated. In this report, we describe the case of a 67-year-old male who relapsed after treatment with tisagenlecleucel as a third-line therapy. We present our approach to treatment after relapse, in which we tried to sustain the circulating chimeric antigen receptor T-cells. This is reflected by the kinetics of the chimeric antigen receptor T-cells during these treatments.